NCT05660421 2024-10-31
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
Vanderbilt-Ingram Cancer Center
M.D. Anderson Cancer Center